About US
Contact us
-
England’s chief medical officer calls for better access to genetic testingEngland’s chief medical officer professor Dame Sally Davies has highlighted the need for routine access to genetic testing to improve diagnosis and treatment of cancer in the UK. Davies urged the cli2017/8/4
-
Novartis and IBM Watson to optimise cancer care and patient outcomesNovartis has partnered with IBM Watson Health on an outcome-based initiative for patients with advanced breast cancer. The collaboration will involve research on a cognitive solution that uses real-w2017/8/4
-
Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' labelPuma Biotechnology grabbed its FDA approval for neratinib, the kinase inhibitor it’s been developing for HER2-positive breast cancer, but that doesn’t mean the newly dubbed Nerlynx will be roaring ont2017/8/3
-
Roche's hold on Avastin, Herceptin sales loosens as FDA panel backs Amgen and Mylan biosimsRoche took a blockbuster double hit Thursday as the FDA’s Oncologic Drugs Advisory Committee recommended an Amgen biosimilar to Avastin in the morning, and then a Mylan biosim to Herceptin in the afte2017/8/3
-
Racing toward a historic CAR-T approval, Novartis wins unanimous FDA panel backingAll eyes in the drug industry turned to the FDA’s Oncologic Drugs Advisory Committee meeting Wednesday, where Novartis won crucial backing for its lead CAR-T drug. By a 10-0 vote, FDA panel experts e2017/8/2
-
Unable to head off the FDA, Ocular Therapeutix gets second CRL for eye drugManufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery. The Bedford, Massachusetts, biotech todaysaidthe FDA h2017/8/2
-
In wake of Opana ER's demise, FDA plans to intensify pharma's opioid-education jobOpioid makers may have a new task that’s partly old, partly new: educating prescribers on the proper use and serious risks of their medications. That’s an extension of the agency’s current requirement2017/8/1
-
Years after accelerated approval debacle, FDA panel backs Pfizer's MylotargSeven years after the FDA pushed Pfizer's Mylotarg off the market for flunking a confirmatory trial, it's in line for a return. An agency panel backed a new approval for the acute myeloid leukemia (AM2017/8/1
-
Pharma hits back at NHS England's cost-cutting overhaulAmid a tough budget situation in England, the pharma industry is challenging a new clampdown for meds projected to cost the country’s health system more than £20 million per year. The Associati2017/7/31
-
Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats upBiogen and AbbVie’s new multiple sclerosis drug Zinbryta faces fresh prescribing restrictions in Europe after regulators there reviewed liver injuries and one death in patients taking the drug. The E2017/7/31